A survey for Actual Usage of Tocilizumab in Adult Still's Disease Using a Japanese Healthcare Database

A survey for Actual Usage of Tocilizumab in Adult Still's Disease Using a Japanese Healthcare Database - A survey for Actual Usage of Tocilizumab in Adult Still's Disease Using a Japanese Healthcare Database

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000045677

Enrollment

Registered

2021-10-07

Start date

2021-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adult Still&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Cohort 1 Patients 16 years and older with having diagnostic codes (ICD-10 codes; M061(Adult Still7s disease: ASD) or M082(systemic Juvenile idiopathic arthritis: sJIA)) in 2017-2021. Cohort 2 Patients 16 years and older with having diagnostic codes (ICD-10 codes; M061(ASD) or M082(sJIA)) and treated with tocilizumab in 2019-2021.

Exclusion criteria

Exclusion criteria: Cohort 2 Patients treated with tocilizumab in the past 6 months.

Design outcomes

Primary

Measure	Time frame
Rate of less than 5mg/day of corticosteroid dosage after 1 year tocilizumab administration	—

Secondary

Measure	Time frame
Analysis of treatment patterns, etc.	—

Countries

Japan

Contacts

Public ContactSatoshi Kondo

CHUGAI PHARMACEUTICAL CO.,LTD. Medical Science Dept.

kondosts@chugai-pharm.co.jp09052181244

Outcome results